- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID) today reported that CNN News has published a story, dated August 12, titled, "Bee, Scorpion and Snake Venom May Hold Cancer Cure."
Highlights from the story include: A scientist at the University of Illinois, Dipanjan Pan, and his team say they may have found a way to stop cancer cell growth, according to a paper presented at the American Chemical Society conference this week.
The work is in very early stages, but has shown success in stopping breast cancer and melanoma cell growth in lab tests. Pan's technique uses nanotechnology to deliver a synthesized element similar to the venom found in bees, snakes and scorpions. Traditional Chinese medicine has used frog venom to fight liver, lung, colon and pancreatic cancers. Alternative doctors in Cuba have used scorpion venom to fight brain tumors.
The properties in venom that destroy cancer cells can have the same effect on healthy cells -- much in the same way chemotherapy causes cell damage, and painful side effects, while treating cancer. But Pan's lab has developed a technique to separate out the important proteins and peptides in the venom so they can be used to stop cancer cell growth. His lab has found a way to synthesize these helpful cells. Attached to the cancer cells, these nanoparticles with the synthesized venom can either slow down or stop cancer cell growth, and may ultimately stop the cancer from spreading.
Unlike chemotherapy, this more targeted technique would, in theory, only affect cancer cells. If it's successful, this natural agent found in venom could become the basis for a whole legion of cancer-fighting drugs. The entire story is available at: www.PetLifePharma.com.
Commenting on the CNN article, Arthur G. Mikaelian, Ph.D., PetLife Founder and CEO, said, "It's exciting to read of yet another mainstream scientist conducting positive ongoing studies related to animal venom. Dipanjan Pan and his team have confirmed the validity of scorpion venom as an effective tool against cancer, joining a long and distinguished list of respected scientists and institutions who are contributing to the global validation of these types of studies.
"Having started our research and development on the Blue Scorpion venom's anti-cancer properties over ten years ago, at PetLife Pharmaceuticals we are proud to be one of the pioneers in the study of venoms for drugs and nutraceuticals and, equally important, the leader in commercialization of venom-based products for cats and dogs -- Escozine for Pets™ -- which suffer from high rates of cancer, as well as our sister company Medolife's Escozine for humans which has been successfully marketed in 40 countries for six years.
"Our patented technology potentiates small molecular peptide Blue Scorpion venom by polarization; this gives the natural compound the power to be effective in causing apoptosis (cancer cell death) up to 95 percent as shown in pre-clinical studies," Dr. Mikaelian added. "This preparation has not shown any adverse effect in human or animal use during many years of clinical observations.
PetLife provides highlights of, and links to, the above news article for informational purposes only, as a courtesy to our shareholders. The Company disclaims any responsibility or liability for the accuracy of, or opinions expressed in, these and all other media articles.
About PetLife Pharmaceuticals, Inc.
PetLife (www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and a spinoff of Medolife Corp.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
For more information, please click here
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015